Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure Yahoo FinanceEli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF Yahoo FinanceSUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity TCTMDEli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free ReutersOzempic could prevent diabetes.

BING NEWS:
  • Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
    On Saturday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced the risk of worsening heart failure events in adults with heart failure ...
    11/18/2024 - 2:10 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News